BioAge Labs (NASDAQ:BIOA) Stock Price Up 8.7% – Here’s What Happened

BioAge Labs, Inc. (NASDAQ:BIOA)’s share price shot up 8.7% on Tuesday . The stock traded as high as $16.85 and last traded at $17.20. 39,262 shares traded hands during mid-day trading, a decline of 95% from the average session volume of 739,205 shares. The stock had previously closed at $15.83.

Analysts Set New Price Targets

BIOA has been the subject of several research analyst reports. Morgan Stanley set a $23.00 price objective on BioAge Labs in a research note on Wednesday, February 4th. Piper Sandler initiated coverage on BioAge Labs in a research note on Tuesday, January 27th. They issued an “overweight” rating on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioAge Labs in a report on Tuesday, January 27th. Wall Street Zen raised BioAge Labs from a “sell” rating to a “hold” rating in a report on Tuesday, February 3rd. Finally, Oppenheimer initiated coverage on shares of BioAge Labs in a research report on Wednesday, February 25th. They issued an “outperform” rating and a $60.00 price objective on the stock. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $46.25.

BioAge Labs Trading Up 1.4%

The business’s fifty day moving average price is $19.67 and its 200-day moving average price is $13.27. The company has a market capitalization of $786.86 million, a P/E ratio of -7.92 and a beta of 1.81.

BioAge Labs (NASDAQ:BIOA) last released its earnings results on Tuesday, March 24th. The company reported ($0.72) EPS for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.11. BioAge Labs had a negative return on equity of 27.86% and a negative net margin of 896.11%.The business had revenue of $3.08 million for the quarter.

Insider Activity

In related news, insider Paul D. Rubin sold 7,433 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $18.75, for a total value of $139,368.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Dov A. Md Goldstein sold 27,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $19.70, for a total value of $531,900.00. Following the completion of the sale, the chief financial officer directly owned 22,408 shares of the company’s stock, valued at approximately $441,437.60. This represents a 54.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 267,540 shares of company stock worth $4,895,168. 20.82% of the stock is currently owned by insiders.

Institutional Investors Weigh In On BioAge Labs

Several institutional investors have recently bought and sold shares of BIOA. Geode Capital Management LLC grew its position in BioAge Labs by 60.8% during the 2nd quarter. Geode Capital Management LLC now owns 453,455 shares of the company’s stock worth $1,873,000 after acquiring an additional 171,426 shares during the last quarter. Intech Investment Management LLC bought a new stake in BioAge Labs in the second quarter valued at approximately $60,000. Stonepine Capital Management LLC boosted its stake in shares of BioAge Labs by 202.2% during the second quarter. Stonepine Capital Management LLC now owns 151,085 shares of the company’s stock valued at $624,000 after purchasing an additional 101,085 shares during the period. Walleye Capital LLC bought a new position in shares of BioAge Labs in the second quarter worth approximately $64,000. Finally, Marshall Wace LLP grew its holdings in shares of BioAge Labs by 324.7% in the second quarter. Marshall Wace LLP now owns 226,789 shares of the company’s stock worth $937,000 after purchasing an additional 173,388 shares during the last quarter.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.